Tiny doses of atropine: unlocking the Eye's response to slow nearsightedness
NCT ID NCT07674966
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study investigates how low doses of atropine eye drops (0.01%, 0.02%, and 0.05%) affect pupil size and the eye's ability to focus in healthy adults aged 18 to 40. Researchers aim to compare different dosing methods and recovery times, and to see if iris color influences the effects. The findings could help optimize atropine treatment for myopia (nearsightedness).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atropine eye drops (0.01%, 0.02%, 0.05%)
What this could lead to
If successful, this could help refine dosing strategies for using low-dose atropine to slow myopia progression in children.
What could go wrong
This is a small, early-phase study in healthy adults, not patients. Results may not translate to real-world myopia treatment or predict long-term effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOPIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, Berkeley
Berkeley, California, 94720-2020, United States